The Marked Chart Wire · Series of events
Series of events · Obesity Drugs
Obesity drug pipeline and access updates
Recent developments in obesity treatments include new distribution partnerships and clinical trial data from major pharmaceutical companies.
Updated
The flow in 3 points
- Foundayo costs $149 per month through Hims & Hers
- Eloralintide phase 2 showed 74% fewer cravings
- Zealand Pharma started Phase 2 ZYNERGY study
What happened, in order
Times are Eastern-
Where it began
Access deal
Eli Lilly and Hims & Hers agreed to sell weight loss medicines via telehealth, with Foundayo at $149 and Zepbound at $299 monthly.
Read the story -
Trial results
Eli Lilly shared phase 2 data for eloralintide, noting 74% of users had fewer cravings and 52% less food noise.
Read the story -
Latest
New study
Zealand Pharma began its Phase 2 ZYNERGY study to test a combination of petrelintide and enicepatide for obesity.
Read the story
How they connect
The sequence moves from a commercial distribution agreement to new clinical data from Eli Lilly, then to a separate trial launch by Zealand Pharma.
The stocks in this series
Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.